Interestingly, we found that APL patients with high SLIT2 expression were associated with cell cycle controllers (CDKN1A, TP53, and TP73), whereas patients with low SLIT2 expression were linked to cell proliferation genes (AKT1, MYB, MIK67, and MAP3K11) and poor APL/AML prognosis marker (FOXM1, AREG, and PIM1). Here, SLIT2 is linked to acute myeloid leukemia.